8-K
Harrow, Inc. (HROW)
View as plain text
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Dateof Report (Date of earliest event reported): August 19, 2021
HARROW
HEALTH, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35814 | 45-0567010 |
|---|---|---|
| (State<br> or other jurisdiction<br><br> <br>of<br> incorporation) | (Commission<br><br> <br>File<br> Number) | (IRS<br> Employer<br><br> <br>Identification<br> No.) |
| 102 Woodmont Blvd., Suite 610 | ||
| --- | --- | |
| Nashville, Tennessee | 37205 | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
Registrant’s telephone number, including area code: (615) 733-4730
NotApplicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol(s) | Name<br> on exchange on which registered |
|---|---|---|
| Common<br> Stock, $0.001 par value per share | HROW | The<br> NASDAQ Global Market |
| 8.625%<br> Senior Notes due 2026 | HROWL | The<br> NASDAQ Global Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company ☐
If any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item8.01 Other Events.
Effective August 19, 2021, the Board of Directors (the “Board”) of Harrow Health, Inc. (the “Company”) appointed Mark L. Baum, the Company’s Chief Executive Officer and a member of the Board, to serve as Chairman of the Board, replacing Dr. Robert J. Kammer in that role. Dr. Kammer will remain a member of the Board.
Item9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
|---|---|
| Item | Description |
| --- | --- |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARROW HEALTH, INC. | |||
|---|---|---|---|
| Dated: | August<br> 23, 2021 | By: | /s/ Andrew R. Boll |
| Andrew<br> R. Boll | |||
| Chief<br> Financial Officer |